Logo
x

Search

Subscribe Now

tumor

Merck Receives the US FDA's Priority Review for Keytruda's (pembrolizumab) sBLA Based on Biomarker Regardless of Tumor Type

Merck Receives the US FDA's Priority Review for Keytruda's (pembrolizumab) sBLA Based on Biomarker Regardless of Tumor Type

  • April 7, 2020
Zai Lab and Novocure's Optune Receive NMPA's Innovative Medical Device Designation for its Tumor Treating Field Delivery System

Zai Lab and Novocure's Optune Receive NMPA's Innovative Medical Device Designation for its Tumor Treating Field Delivery System

  • August 12, 2019
Regeneron to Present Results of Libtayo (cemiplimab) for Six Tumor Indications at ESMO 2018

Regeneron to Present Results of Libtayo (cemiplimab) for Six Tumor Indications at ESMO 2018

  • October 9, 2018
AstraZeneca to acquire EsoBiotec for ~$1B

    AstraZeneca to acquire EsoBiotec for ~$1B

    • March 18, 2025
    HUTCHMED Reports Enrollment Completion in P-II Trial of Fanregratinib for Intrahepatic Cholangiocarcinoma in China

      HUTCHMED Reports Enrollment Completion in P-II Trial of Fanregratinib for Intrahepatic Cholangiocarcinoma in China

      • March 7, 2025
      ITM Reports Topline Data from P-III (COMPETE) Trial of ITM-11 at the ENETS 2025 Conference

        ITM Reports Topline Data from P-III (COMPETE) Trial of ITM-11 at the ENETS 2025 Conference

        • March 6, 2025
        Epitopea Partners with Merck to Discover Cryptigen Tumor-Specific Antigens

          Epitopea Partners with Merck to Discover Cryptigen Tumor-Specific Antigens

          • February 20, 2025
          ITM Reports Topline Data from P-III (COMPETE) Trial of ITM-11 to Treat Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

            ITM Reports Topline Data from P-III (COMPETE) Trial of ITM-11 to Treat Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tu...

            • January 29, 2025
            Avenzo Therapeutics Join Forces with DualityBio to Develop AVZO-1418 (DB-1418) for Solid Tumors

              Avenzo Therapeutics Join Forces with DualityBio to Develop AVZO-1418 (DB-1418) for Solid Tumors

              • January 8, 2025
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.